Asset sale Completed
Cosette Pharmaceuticals acquisition of Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup)
US$35m consideration
Announced 8 Apr 2026
Advisers
Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup)
Target
- Financial adviser
- Legal adviser
Cosette Pharmaceuticals
Acquirer
Not disclosed
- Target
- Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup)
- Acquirer
- Cosette Pharmaceuticals
- Seller
- Assertio Holdings
- Target based in
- United States
- Buyer based in
- United States
- Seller based in
- United States
- Completed
- 8 Apr 2026
- Sector
- Pharma
In the league tables
Similar deals
- Subsidiary of Piramal Pharma acquisition of Worldwide rights to Kenalog Apr 2026 · US$35m · Pharma
- Harrow acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg Aug 2026 · US$30m · Pharma
- TELI Pharmaceuticals and Telomir Pharmaceuticals merger US$47.1m · Biotech
- Aurinia Pharmaceuticals acquisition of Kezar Life Sciences Mar 2026 · US$51.5m · Biotech
- Esperion Therapeutics acquisition of Corstasis Therapeutics Mar 2026 · US$75m · Pharma
Sources
- 9 Apr 2026 Tender offer communication (SC TO-C), Assertio Holdings, Inc. sec.gov
- 9 Apr 2026 Press release (EX-99.1, exhibit), Assertio Announces Agreement to be Acquired sec.gov

